Gene and Cell Therapy for Lymphedema
| Project/Area Number |
15K10229
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Cardiovascular surgery
|
|---|
| Research Institution | Asahikawa Medical College |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
|---|
| Keywords | リンパ管内皮細胞 / iPS細胞 / リンパ管学 / リンパ浮腫 / 遺伝子治療 |
|---|
| Outline of Final Research Achievements |
The purpose of this study is to induce iPS cells into lymphatic endothelial cells by transfection of hepatocyte growth factor (HGF) plasmid DNA. 1) We could not obtain the mouse iPS cell line of HGF stable expression. 2) We could not establish the lymphatic endothelial cell line from mouse iPS by co-culture method with OP-9. 3) When HGF was expressed in iPS cell transiently, lymphatic cell markers, such as Sox18, FoxC2, VEGFR3, and Prox1, were up-regulated at 5-day after transfection, but these up-regulation were neutralized at 14-day.
|
Report
(4 results)
Research Products
(3 results)
